## **Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## In the Claims:

- 1. (Cancelled).
- 2. (Currently Amended) A compound or salt thereof selected from the group consisting of

$$\begin{array}{c} F \\ F \\ \end{array}$$

3. (Currently amended) A compound selected from the group consisting of tert-butyl 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]pyrrolidine-1-carboxylate;

8-{3-[3-(3,4-dichlorophenyl)-1-(2-furoyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[3-(3,4-dichlorophenyl)-1-(isoxazol-5-ylcarbonyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

```
8-{3-[3-(3,4-dichlorophenyl)-1-(1H-pyrrol-2-ylcarbonyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;
```

8-{3-[3-(3,4-dichlorophenyl)-1-pentanoylpyrrolidin-3-yl]propyl}-1-[3-

(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[3-(3,4-dichlorophenyl)-1-(2-furoyl)pyrrolidin-3-yl]propyl}-1-[3-

(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[3-(3,4-dichlorophenyl)-1-pentanoylpyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-(3-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one;

3-acetyl-8-{3-[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-(3-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one;

8-{3-[1-(1,3-benzoxazol-2-yl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-(2-{[3-(3,4-dichlorophenyl)-1-(2-furoyl)pyrrolidin-3-yl]oxy}ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-(2-{[1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxy}ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-(2-{[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxy}ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-(2-{[3-(3,4-dichlorophenyl)-1-(phenylsulfonyl)pyrrolidin-3-yl]oxy}ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;


8-(2-{[3-(3,4-dichlorophenyl)-1-(2-furoyl)pyrrolidin-3-yl]oxy}ethyl)-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one;

- 8-(2-{[1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxy}ethyl)-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one; <u>and</u>
  8-(2-{[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxy}ethyl)-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one; <u>and</u>
  8-(2-{[3-(3,4-dichlorophenyl)-1-(phenylsulfonyl)pyrrolidin-3-yl]oxy}ethyl)-1-(3-
- methoxyphenyl) 1,3,8 triazaspiro[4.5]decan-4-one.

  4. (Currently Amended) The compound of claim 4 48 wherein the B ring is pyrrolidine.
- 5. (Original) The compound of claim 4 wherein R<sup>9</sup> is H.
- 6. (Cancelled).
- 7. (Currently Amended) The compound of claim 4 <u>48</u> wherein R<sup>1</sup> is aryl or a <u>substituted</u> aryl.
- 8. (Original) The compound of claim 7 wherein R<sup>1</sup> is phenyl mono- or di- substituted with halogen.
- 9. (Original) The compound of claim 8 wherein R<sup>1</sup> is phenyl di-substituted with Cl.
- 10. (Currently Amended) The compound of claim  $4 \underline{48}$  wherein  $-(Y)_m$ - $R^3$  is selected from the group consisting of

11. (Currently Amended) The compound of claim  $4 \underline{48}$  wherein  $-(Y)_m$ - $R^3$  is selected from the group consisting of

- 12. (Currently Amended) The compound of claim  $4 \underline{48}$  wherein m is 1, Y is -C(O)-, and  $R^3$  is either aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted, with an optionally substituted alkyl, or an optionally substituted cycloalkyl.
- 13. (Cancelled).
- 14. (Cancelled).
- 15. (Currently Amended) The compound of claim  $4 \underline{48}$  wherein m is 1, Y is -C(O)O-, and  $R^3$  is optionally substituted alkyl or optionally substituted aryl.
- 16.-24. (Cancelled).
- 25. (Currently Amended) The compound of claim 4 <u>48</u> wherein the A ring, with an asterisk indicating the point of substitution, is selected from the group consisting of



26.- 28. (Cancelled).

29. (Currently amended) The compound of claim  $\frac{27}{48}$  wherein the A ring ring in combination with  $R^2$  is selected from the group consisting of[[.]]

Serial No. 10/538,134 Attorney Docket No. PU4976USw

30.- 42. (Cancelled).

- 43. (Currently Amended) A pharmaceutical composition comprising a
   pharmaceutically effective amount of a compound according to claims 1-30 claim
   48 together with a pharmaceutically acceptable carrier.
- 44. (Currently Amended) The pharmaceutical composition according to claim 42 43 in the form of a tablet or capsule.
- 45. (Currently Amended) The pharmaceutical composition according to claim 42 43in the form of a liquid.
- 46. 47. (Cancelled).
- 48. (New) A compound of formula (I)

$$R^{3}-(Y)_{m}$$
  $N$   $B$   $X-N$   $A$   $N$   $R^{0}$   $R^{0}$   $R^{0}$   $R^{0}$ 

and pharmaceutically acceptable derivatives thereof, wherein

X is  $(CH_2)_3$ ;

Ring A is a saturated, 6-membered monocyclic ring having one ring nitrogen;

Ring B is a saturated 4 or 5 membered ring containing the depicted ring nitrogen;

R<sup>1</sup> is a phenyl or a phenyl substituted with mono- or di- halogen;

Y is -C(O)- or -C(O)-O, and m is 1;

 $R^3$  is H,  $-N(R^0)_2$ ,  $-N(R^0)C(O)R^0$ , -CN, halogen,  $CF_3$ , alkyl optionally substituted by one or more groups selected from  $R^7$  or -S-aryl optionally substituted by  $-(CH_2)_{1-6}$ -  $N(R^0)SO_2(R^0)$ , alkenyl optionally substituted by one or more groups selected from  $R^7$  or -S-aryl optionally substituted by  $-(CH_2)_{1-6}-N(R^0)SO_2(R^0)$ , alkynyl optionally substituted by one or more groups selected from  $R^7$  or -S-aryl optionally substituted by  $-(CH_2)_{1-6}-N(R^0)SO_2(R^0)$ , cycloalkyl or carbocyclyl optionally substituted by one or more  $R^8$ , aryl optionally substituted by one or more  $R^6$ , heteroaryl optionally substituted by one or more  $R^8$ ;

each R<sup>6</sup> is independently selected from the group consisting of halogen, -CF<sub>3</sub>, -OCF<sub>3</sub>,

```
-\mathsf{OR}^0, -(\mathsf{CH}_2)_{1-6}-\mathsf{OR}^0, -\mathsf{SR}^\circ, -(\mathsf{CH}_2)_{1-6}-\mathsf{SR}^0, -\mathsf{SCF}_3, -\mathsf{R}^0, \text{ methylenedioxy},\\ \text{ethylenedioxy}, -\mathsf{NO}_2, -\mathsf{CN}, -(\mathsf{CH}_2)_{1-6}-\mathsf{CN}, -\mathsf{N}(\mathsf{R}^0)_2, -(\mathsf{CH}_2)_{1-6}-\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{NR}^\circ\mathsf{C}(\mathsf{O})\mathsf{R}^0,\\ -\mathsf{NR}^0(\mathsf{CN}), -\mathsf{NR}^0\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{NR}^\circ\mathsf{C}(\mathsf{S})\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{NR}^\circ\mathsf{CO}_2\mathsf{R}^0, -\mathsf{NR}^0\mathsf{NR}^0\mathsf{C}(\mathsf{O})\mathsf{R}^0,\\ -\mathsf{NR}^0\mathsf{NR}^0\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{NR}^0\mathsf{NR}^0\mathsf{CO}_2\mathsf{R}^0, -\mathsf{C}(\mathsf{O})\mathsf{C}(\mathsf{O})\mathsf{R}^0, -\mathsf{C}(\mathsf{O})\mathsf{CH}_2\mathsf{C}(\mathsf{O})\mathsf{R}^0,\\ -(\mathsf{CH}_2)_{0-6}\mathsf{CO}_2\mathsf{R}^0, -\mathsf{O-C}(\mathsf{O})\mathsf{R}^0, -\mathsf{C}(\mathsf{O})\mathsf{R}^0, -\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)_2,\\ -(\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)\mathsf{OH}, -\mathsf{C}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)\mathsf{SO}_2\mathsf{R}^0, -\mathsf{OC}(\mathsf{O})\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{S}(\mathsf{O})_{\mathsf{t}}\mathsf{N}^0, -\mathsf{S}(\mathsf{O})_{\mathsf{t}}\mathsf{N}(\mathsf{R}^0)\mathsf{OR}^0,\\ -\mathsf{S}(\mathsf{O})_{\mathsf{t}}\mathsf{N}(\mathsf{R}^0)\mathsf{C}(\mathsf{O})\mathsf{R}^0, -\mathsf{S}(\mathsf{O})_{\mathsf{t}}\mathsf{N}(\mathsf{R}^0)\mathsf{OR}^0, -\mathsf{NR}^0\mathsf{SO}_2\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{NR}^0\mathsf{SO}_2\mathsf{R}^0, -\mathsf{C}(=\mathsf{S})\mathsf{N}(\mathsf{R}^0)_2,\\ -\mathsf{C}(=\mathsf{NH})-\mathsf{N}(\mathsf{R}^0)_2, -(\mathsf{CH}_2)_{1-6}-\mathsf{C}(\mathsf{O})\mathsf{R}^0, -\mathsf{C}(=\mathsf{N-OR}^0)-\mathsf{N}(\mathsf{R}^0)_2, -\mathsf{O-(\mathsf{CH}_2)_{0-6}-\mathsf{SO}_2\mathsf{N}(\mathsf{R}^0)_2,\\ -(\mathsf{CH}_2)_{1-6}-\mathsf{NHC}(\mathsf{O})\mathsf{R}^0, \text{ and} -\mathsf{SO}_2\mathsf{N}(\mathsf{R}^0)_2 \text{ wherein the two }\mathsf{R}^0 \text{ s on the same nitrogen}\\ \text{are optionally taken together to form a 5-8 membered saturated, partially}\\ \text{saturated, or aromatic ring having additional 0-4 heteroatoms selected from}\\ \text{oxygen, phosphorus, nitrogen, or sulfur;}\\ \mathsf{R}^7 \text{ is independently selected from the group consisting of halogen, -CF}_3, -R^0, -\mathsf{OR}^0, -\mathsf{OR}^0,
```

each  $R^7$  is independently selected from the group consisting of halogen,  $-CF_3$ ,  $-R^0$ ,  $-CR^0$ ,  $-CCF_3$ ,  $-(CH_2)_{1-6}-CR^0$ ,  $-SR^0$ ,  $-SCF_3$ ,  $-(CH_2)_{1-6}-SR^0$ , aryl optionally substituted by  $R^6$ , methylenedioxy, ethylenedioxy,  $-NO_2$ , -CN,  $-(CH_2)_{1-6}-CN$ ,  $-N(R^0)_2$ ,  $-(CH_2)_{1-6}-CN$ ,  $-N(R^0)_2$ ,  $-NR^0C(O)R^0$ ,  $-NR^0(CN)$ ,  $-NR^0C(O)N(R^0)_2$ ,  $-NR^0NR^0C(SN(R^0)_2$ ,  $-NR^0NR^0C(SN(R^0)_2$ ,  $-NR^0NR^0C(SN(R^0)_2$ ,  $-NR^0NR^0C(SN(R^0)_2$ ,  $-C(SN(R^0)_2$ ,  $-C(SN(R^0)_2$ ,  $-C(SN(R^0)_2$ ),  $-C(SN(R^0)_2$ , and  $-SN(R^0)_2$ , wherein the two  $-SN(R^0)_2$ , and  $-SN(R^0)_2$ , and and additional  $-SN(R^0)_2$ , and additional  $-SN(R^0)_2$ 

each  $R^8$  is independently selected from  $R^7$ , =O, =S, =N( $R^0$ ), and =N(CN);  $R^9$  is H;

each R<sup>0</sup> is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, and heterocyclylalkyl, wherein each member of R<sup>0</sup> except H is

optionally substituted by one or more R\*, OR\*, N(R\*)<sub>2</sub>, =O, =S, halo, CF<sub>3</sub>, NO<sub>2</sub>, CN, -C(O)R\*, -CO<sub>2</sub>R\*, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-aralkyl, -S(O)<sub>t</sub>-aryl, -S(O)<sub>t</sub>-heteroaryl, -NR\*SO<sub>2</sub>R\*, -NR\*C(O)R\*, -NR\*C(O)N(R\*)<sub>2</sub>, -N(R\*)C(S)N(R\*)<sub>2</sub>, -NR\*CO<sub>2</sub>R\*, -NR\*NR\*C(O)R\*, -NR\*NR\*C(O)N(R\*)<sub>2</sub>, -NR\*NR\*CO<sub>2</sub>R\*, -C(O)C(O)R\*, -C(O)CH<sub>2</sub>C(O)R\*, -C(O)N(R\*)N(R\*)<sub>2</sub>, -C(O)N(R\*)<sub>2</sub>, -C(O)N(R\*)<sub>2</sub>, -SO<sub>2</sub>N(R\*)<sub>2</sub> wherein the two R\*s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen or sulfur; each R\* is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl.